Quark Pharmaceuticals this week announced the release of phase I data showing its delayed graft function prophylaxis QPI-1002 to be safe in kidney transplant recipients.
QPI-1002, which is designed to silence p53, was tested in 40 transplant recipients of kidneys from deceased donors. Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.
The full data from the study are currently under analysis, the company added.